Elacestrant Dosing and Eligibility in the EMERALD Trial
Elacestrant should be administered at 345 mg orally once daily with food in adult patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who have progressed after at least one line of endocrine therapy that included a CDK4/6 inhibitor. 1
Eligibility Criteria
Required Patient Characteristics
- Postmenopausal women or adult men with ER-positive, HER2-negative advanced or metastatic breast cancer 1
- Documented ESR1 mutation detected by validated testing (liquid biopsy or tissue) 1, 2
- Disease progression following at least one line of endocrine therapy 1
- Mandatory prior CDK4/6 inhibitor exposure in combination with endocrine therapy 2
Treatment History Requirements
- 1-2 prior lines of endocrine therapy for advanced/metastatic disease 2
- ≤1 prior chemotherapy line for metastatic disease 2
- Prior CDK4/6 inhibitor treatment is mandatory, not optional 2
Dosing Regimen
Standard Dosing
- 345 mg tablet taken orally once daily 1
- Must be taken with food (increases bioavailability by 22% for AUC) 1
- Continue until disease progression or unacceptable toxicity 1
Dose Modifications
- Moderate hepatic impairment (Child-Pugh B): Reduce dose to 86 mg once daily 1
- Severe hepatic impairment (Child-Pugh C): Avoid use entirely 1
- Mild hepatic impairment (Child-Pugh A): No dose adjustment needed 1
Management of Adverse Events
Dose interruption, reduction, or permanent discontinuation may be required for adverse reactions 1. The most common grade 3/4 adverse events occurred in only 7.2% of patients, with treatment discontinuation due to toxicity in just 3.4% 2.
Clinical Context and Efficacy
The benefit is most pronounced in patients with ESR1 mutations who received prior CDK4/6 inhibitor therapy for ≥12 months, where median PFS was 8.6 months with elacestrant versus 1.9 months with standard endocrine therapy (HR 0.41) 3. This represents a clinically meaningful improvement across all subgroups evaluated, including those with visceral metastases, multiple metastatic sites, PIK3CA mutations, and various ESR1 mutation subtypes 3.
Critical Selection Point
ESR1 mutation testing is mandatory before initiating elacestrant 1. The FDA approval is specifically restricted to patients with documented ESR1 mutations, as the benefit-risk assessment in ESR1-wild-type patients was not favorable 4. Patients without ESR1 mutations should not receive elacestrant and should be considered for alternative therapies such as fulvestrant plus CDK4/6 inhibitor (if CDK4/6 inhibitor-naive) or other targeted combinations 5.
Safety Monitoring
- Monitor lipid profile before starting treatment and periodically thereafter (elacestrant causes hypercholesterolemia and hypertriglyceridemia) 1
- Avoid concomitant use with strong or moderate CYP3A4 inducers or inhibitors 1
- Most common adverse reactions include musculoskeletal pain, nausea, increased cholesterol, and fatigue 1
Elacestrant represents the first oral selective estrogen receptor degrader demonstrating superior progression-free survival versus standard endocrine therapy in this heavily pretreated population 2, 4, with real-world data confirming durable benefits consistent with the pivotal trial 6, 7.